Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)
TipRanksApr 26 07:50 ET
Express News | Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
BenzingaApr 25 08:08 ET
Express News | Roivant Sciences Ltd - Topline Results Are Expected by End of Calendar Year 2024
ReutersApr 25 08:03 ET
Express News | Roivant and Kinevant Sciences Complete Enrollment in Resolve-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
ReutersApr 25 08:03 ET
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
7 analysts have expressed a variety of opinions on Roivant Sciences (NASDAQ:ROIV) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table encapsulates the
BenzingaApr 22 11:01 ET
Express News | HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
Moomoo 24/7Apr 22 06:34 ET
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
TipRanksApr 22 06:20 ET
Institutional Investors in Roivant Sciences Ltd. (NASDAQ:ROIV) Lost 7.3% Last Week but Have Reaped the Benefits of Longer-term Growth
Key Insights Significantly high institutional ownership implies Roivant Sciences' stock price is sensitive to their trading actions 52% of the business is held by the top 7 shareholders Insiders
Simply Wall StApr 19 07:20 ET
Roivant Sciences Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since August 2022 -- Data Talk
Roivant Sciences Ltd. (ROIV) is currently at $10.58, down $0.13 or 1.17% --Would be lowest close since April 1, 2024, when it closed at $10.43 --Currently down eight consecutive days; down 9.84% ove
Dow JonesApr 17 14:49 ET
Unusual Options Activity: SBUX, ROIV and Others Attract Market Bets, SBUX V/OI Ratio Reaches 111.0
EST Apr 5th Closing Delivery - In the last three hours of trading, 6 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
moomoo NewsApr 5 16:30 ET
Arbutus Biopharma Jumps After Patent Victory in Fight With Moderna
Seeking AlphaApr 3 12:27 ET
Express News | Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $18
Moomoo 24/7Apr 3 11:18 ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
TipRanksApr 3 08:11 ET
Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.
Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 3 07:15 ET
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating
Roivant Sciences (ROIV) has an average rating of Buy and price targets ranging from $12 to $23, according to analysts polled by Capital IQ. Price: 11.16, Change: +0.24, Percent Change: +2.2
MT NewswiresApr 3 07:11 ET
Buy Rating Affirmed for Roivant Sciences Amid Brepocitinib Success and Strategic Share Repurchase Program
TipRanksApr 3 06:26 ET
Express News | Deutsche Bank Maintains Buy on Roivant Sciences, Raises Price Target to $15
Moomoo 24/7Apr 3 05:14 ET
Roivant Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/03/2024 35.99% Deutsche Bank $14 → $15 Maintains Buy 03/25/2024 108.52% Truist Securities → $23 Reitera
BenzingaApr 3 05:14 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Inari Medical (NARI) and Roivant Sciences (ROIV)
TipRanksApr 3 05:03 ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)
TipRanksApr 2 16:10 ET
No Data
No Data